Sarah Lund

Dr. Sarah Lund

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Surgery
Verified
Journal Article
Closed access
SLSarah Lund
Sarah Lund
JDJonathan D. D’angelo
Jonathan D. D’angelo
KJKristen Jogerst
Kristen Jogerst
SWSusanne G. Warner
Susanne G. Warner
RBRebecca Busch
Rebecca Busch
ADAnne-Lise D. D’angelo
Anne-Lise D. D’angelo

1 December 2021 in The American Journal of Surgery
Verified
Journal Article
Closed access
SLSarah Lund
Sarah Lund
MYMaria Yan
Maria Yan
JDJonathan D'Angelo
Jonathan D'Angelo
TWTianke Wang
Tianke Wang
MHM. Susan Hallbeck
M. Susan Hallbeck
MZMartin Zielinski
Martin Zielinski

16 April 2021 in The American Surgeon™
Verified
Journal Article
Open access
PDF file
SLSarah Lund
Sarah Lund
TMTaleen MacArthur
Taleen MacArthur
MFMarianna Martini Fischmann
Marianna Martini Fischmann
JMJustin Maroun
Justin Maroun
JDJohnny Dang
Johnny Dang
DSDaniel Stephens
Daniel Stephens
To describe the effect of the COVID-19 pandemic on emergency general surgery operative volumes during governmental shutdowns secondary to the pandemic and characterize differences in disease severity, morbidity, and mortality during this time compared to previous years. This retrospective cohort study compares patients who underwent emergency general surgery operations at a tertiary hospital from March 1st to May 31st of 2020 to 2019. Average emergent cases per day were analyzed, comparing identical date ranges between 2020 (pandemic group) and 2019 (control group). Secondary analysis was performed analyzing disease severity, morbidity, and mortality. From March 1st to May 31st, 2020, 2.5 emergency general surgery operations were performed on average daily compared to 3.0 operations on average daily in 2019, a significant decrease (P = .03). No significant difference was found in presenting disease severity, morbidity, or mortality between the pandemic and control groups. This study demonstrates a decrease of 65% in emergency general surgery operations during governmental restrictions secondary to the COVID-19 pandemic. This decrease in operations was not associated with worse disease severity, morbidity, or mortality.

20 May 2022 in Journal of Surgical Research
Verified
Journal Article
Closed access
SLSarah Lund
Sarah Lund
ADAnne-Lise D'ANgelo
Anne-Lise D'ANgelo
RBRebecca Busch
Rebecca Busch
RFRebecca Friberg
Rebecca Friberg
JDJonathan D'ANgelo
Jonathan D'ANgelo

2 June 2023 in Annals of Surgery
Verified
Journal Article
Open access
BNBindi Naik-Mathuria
Bindi Naik-Mathuria
AUAlan F Utria
Alan F Utria
PEPeter F. Ehrlich
Peter F. Ehrlich
JAJennifer H. Aldrink
Jennifer H. Aldrink
AMAndrew Murphy
Andrew Murphy
DRDavid H. Rothstein
David H. Rothstein
Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.

1 December 2019 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
TTTheresa Tran
Theresa Tran
SLSarah Lund
Sarah Lund
MNMicah D. Nichols
Micah D. Nichols
TKTobias Kummer
Tobias Kummer